Overview

Formoterol in Diabetes

Status:
NOT_YET_RECRUITING
Trial end date:
2027-08-01
Target enrollment:
Participant gender:
Summary
The purpose of the study is to evaluate if formoterol fumarate is effective in treating patients with diabetic kidney disease. Study participants will be randomly assigned to either receive formoterol fumarate (in addition to their current standard of care treatment) or standard of care treatment only. Study participants will have a 50% chance of receiving formoterol fumarate and a 50% chance of not receiving formoterol fumarate. Both groups will continue their standard of care treatment during the study. The primary goal is to gather data on feasibility and effect sizes to properly power a future clinical trial.
Phase:
PHASE2
Details
Lead Sponsor:
Medical University of South Carolina
Collaborator:
Dialysis Clinic, Inc.